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CASE REPORT
Successful treatment of early allograft 
dysfunction with cinacalcet in a patient 
with nephrocalcinosis caused by severe 
hyperparathyroidism: a case report
Boonyarit Cheunsuchon1* and Suchai Sritippayawan2
Abstract 
Background: Hyperparathyroidism is common in patients undergoing kidney transplantation. Occasionally, this 
condition can cause early allograft dysfunction by inducing calcium phosphate deposition in the allograft, which 
results in nephrocalcinosis. Although nephrocalcinosis occurs occasionally in kidney allografts, it has only rarely been 
reported in the literature.
Case presentation: Here, we present the case of a 58-year-old Thai woman with severe hyperparathyroidism who 
received a living-related kidney transplant from her 35-year-old son. Our patient developed allograft dysfunction on 
day 2 post-transplantation despite good functioning graft on day 1. Allograft biopsy showed extensive calcium phos-
phate deposition in distal tubules. She was treated with cinacalcet (a calcimimetic agent) and aluminum hydroxide. 
Allograft function was restored to normal within 1 week after transplantation with greatly reduced intact parathyroid 
hormone level.
Conclusion: Hyperparathyroidism in early functioning allograft causes elevated calcium and phosphate concentra-
tion in distal tubules resulting in nephrocalcinosis. The massive calcium phosphate precipitation obstructs tubular 
lumens, which leads to acute tubular dysfunction. Treatment of nephrocalcinosis with cinacalcet is safe and may 
improve this condition by increasing serum phosphate and reducing serum calcium and intact parathyroid hormone.
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Background
Advances in tissue typing, crossmatching techniques, 
and immunosuppression have significantly reduced the 
risk of early renal allograft dysfunction due to immuno-
logical injury [1]. Although short-term graft survival is 
markedly improved, long-term graft outcome remains 
uncertain [1]. Recently, many studies have demonstrated 
the importance of nonimmunological processes (e.g., 
drug toxicity, infections, and recurrent/de novo glomer-
ular diseases) that can cause allograft deterioration [2]. 
Nephrocalcinosis is a common finding in renal allografts, 
with an incidence of 80% at 10 years after transplantation 
[3]. However, nephrocalcinosis is rarely recognized as the 
cause of early allograft dysfunction [4]. Here, we present 
a histological finding of nephrocalcinosis in a renal allo-
graft of a patient with early graft dysfunction. Clinical 
findings, possible etiologies, pathogenesis, and treatment 
are all briefly discussed.
Case presentation
A 58-year-old Thai woman developed end-stage renal 
disease from lupus nephritis and had been on hemo-
dialysis for 2  years. She had markedly elevated serum 
intact parathyroid hormone (iPTH) of 113.8  pmol/L 
(1.6–6.9  pmol/L), increased serum calcium (Ca) of 
2.65  mmol/L (2.10–2.37  mmol/L), and a phosphorus 
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(P) level of 1.39  mmol/L (1.13–1.78  mmol/L). She was 
on Lanthanum carbonate, later converted to aluminum 
hydroxide, but was not on 1 alpha cholecalciferol, vita-
min D analogs or calcium supplements. Daily urine out-
put was 130 mL and her urine pH was high at 7.5 without 
urinary tract infection or sodium bicarbonate use. On 26 
March 2014, our patient received a renal transplant from 
her haplo-identical and compatible blood group 35-year-
old son. The radionuclide renogram demonstrated 
normal function of both of the donor’s kidneys. Pretrans-
plant luminex crossmatch and panel reactive antibody 
tests were negative. Parathyroid sestamibi scan was not 
done because the doctor and patient did not want to do 
a parathyroidectomy. Cinacalcet (50  mg, once a day), a 
calcimimetic agent, and aluminum hydroxide (Al(OH)3) 
(1000 mg, three times a day) were prescribed for 2 days 
prior to transplantation. Serum Ca, P, and iPTH were 
decreased to 2.20, 1.74  mmol/L, and 92  pmol/L at the 
time of transplantation, respectively (Fig.  1). Induction 
therapy consisted of tacrolimus, mycophenolate mofetil, 
and steroid without interleukin-2 receptor antagonists as 
indicated in institutional protocol.
The patient had immediate graft function with 3000 mL 
of urine during day 1 after transplantation. However, urine 
output decreased to 1150 mL on day 2, with serum Ca, P, 
and iPTH levels increased to 2.33 mmol/L, 1.65 mmol/L, 
and 137.4 pmol/L, respectively (Fig. 1). Serum creatinine 
(SCr) was significantly elevated to 280 µmol/L on day 4. 
Doppler ultrasound of the transplanted kidney showed 
no hydronephrosis or vessel-related problems. Cinacalcet 
(25 mg) and Al(OH)3 were restarted again on day 2. Intra-
venous furosemide was also prescribed to enhance urine 
output. Tacrolimus level were 6.5–11.9 ng/mL. Hemodi-
alysis was started and allograft biopsy was performed on 
day 2 after transplantation. The graft biopsy contained 
25 glomeruli with no presence of glomerulitis or fibrin 
thrombi. There were, however, more than 20 foci of intra-
tubular basophilic crystals (Fig.  2a). The crystals were 
positive for von Kossa stain, indicating calcium phosphate 
precipitation (Fig.  2b). Under polarized light, crystals 
showed no birefringence that is characteristic of calcium 
oxalate. Interestingly, all of the crystals were located in 
the distal tubules. There was no evidence of tubular injury 
or rejection. Immunofluorescence studies for IgG, IgA, 
IgM, C3, C1q, kappa, lambda, fibrinogen, and C4d were 
all negative. The histopathological diagnosis was nephro-
calcinosis caused by intratubular precipitation of calcium 
phosphate crystals, most likely due to severe hyperparath-
yroidism. Urine pH before and 1 day after transplantation 
was 7.5 and 6.0, respectively. Our patient did not use any 
phosphate-containing laxatives. We withheld the cinacal-
cet for 24 h due to a high urine calcium/creatinine (Ca/Cr) 
ratio (0.57 mmol/mmol), but restarted later after the ratio 
was decreased to 0.08 and continued for 1 week without 
any change in immunosuppressive agents. SCr and iPTH 
declined to less than 176.8  µmol/L and 21.2  pmol/L, 
respectively, while serum Ca, P, and urine pH were main-
tained between 2.10–2.25 mg/dL, 0.87–1.32 mmol/L, and 
5.5–6.0, respectively. Only one hemodialysis treatment 
was required.
Fig. 1 Clinical course and laboratory findings before and after kidney transplantation. The solid and dash black lines demonstrate the duration of 
cinacalcet (25 mg/day) and furosemide (250–1000 mg/day) treatments, respectively
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At 2  years after transplantation, our patient has 
slightly high serum iPTH (13.8–21.2  pmol/L) and 
Ca (2.65  mmol/L) levels, with low level of serum P 
(0.84  mmol/L). Current immunosuppressive agents 
include tacrolimus, mycophenolate mofetil, and 
prednisolone.
Discussion
Nephrocalcinosis can be found as early as 6  weeks (6% 
in protocol biopsies) after transplantation [5]. The inci-
dence progressively increases to almost 80% by 10 years 
after transplantation [3]. The presence of nephrocalci-
nosis in renal allografts was found to be associated with 
chronic allograft nephropathy [5]. Although nephrocal-
cinosis effect was not significant in the short-term, the 
long-term consequences were unclear [6]. A possible eti-
ology of nephrocalcinosis in this patient may have been 
metabolic derangement associated with severe hyper-
parathyroidism. Nephrocalcinosis was more frequently 
seen in allograft patients with hyperparathyroidism than 
in those without this condition [5, 6]. Hyperparathy-
roidism increases the filtered load of calcium from high 
serum calcium level and decreases phosphate reabsorp-
tion in proximal tubules, both of which elevate calcium 
and phosphate concentrations in distal tubules. Our 
patient also had high urine pH (7.5) before transplanta-
tion, which enhanced calcium phosphate precipitation. 
Unfortunately, we have no data on urine citrate, ammo-
nium, and sulfate levels, which might help to indicate 
the cause of the high urine pH in this patient. Calcium 
phosphate precipitation also causes tubular cell injury, 
which causes the distal tubules to express proteins, 
such as osteopontin and hyaluronan. These molecules 
promote calcium phosphate adhesion to the surface of 
tubular cells [7]. Massive calcium phosphate precipita-
tion causes tubular obstruction, which leads to acute 
allograft dysfunction.
Calcineurin inhibitors were associated with nephroc-
alcinosis in renal allografts. However, the incidence was 
decreased in later study and found not to be different 
from calcification due to acute tubular necrosis [8]. This 
was probably the result of reduced dose of immunosup-
pressive agents used in current practice.
Hyperparathyroidism is common in patients undergo-
ing renal transplantation. Association has been estab-
lished between hyperparathyroidism and delayed graft 
function [9]. Although some reports appear in the lit-
erature [4, 10–13], all of the reports are single-patient 
case reports (none are large case series) of patients with 
early graft dysfunction and nephrocalcinosis (Table  1). 
Among those patients, nephrocalcinosis was detected 
as early as 5 days after transplantation. Four of 5 cases 
showed concurrent lesions (3 acute tubular necrosis, 1 
borderline rejection). Serum calcium and phosphate 
levels varied from normal to markedly increased. Two 
patients had improved graft function after supportive 
treatment and two others required parathyroidectomy. 
Only one patient had graft failure, which was found to 
be caused by gradual increase in calcium crystal deposi-
tion in the follow-up biopsy.
Cinacalcet is a novel phenylalkylamine type II calci-
mimetic agent that allosterically modulates the calcium 
sensing receptor by increasing the sensitivity of the 
receptor to extracellular calcium, which leads to sup-
pression of PTH transcription, secretion, and parathy-
roid gland hyperplasia. Activation of the calcium sensing 
Fig. 2 a Numerous intratubular calcium crystals are noted in the tubular lumens. The absence of interstitial inflammatory cell infiltration rules out 
acute T cell-mediated rejection (H&E stain, original magnification ×200). b Presence of calcium phosphate crystals proven by von Kossa staining 
(von Kossa stain ×400)
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receptor inhibits phosphate reabsorption at the proximal 
tubule and sodium chloride reabsorption at the thick 
ascending limb of Henle loop, which promotes calciuria 
as a result of the reduction in passive paracellular calcium 
reabsorption. Cinacalcet was approved by the United 
States Food and Drug Administration for treatment of 
parathyroid cancer and hyperparathyroidism in end-
stage renal disease patients [14]. The benefit of a calcimi-
metic agent in post-renal transplant hyperparathyroidism 
was demonstrated in a randomized controlled trial [15]. 
In that study, cinacalcet demonstrated an ability to sig-
nificantly increase serum phosphorus level and decrease 
serum calcium and iPTH over the study’s 52-week dura-
tion. In contrast to results from other case reports and 
retrospective studies, three studies in nephrocalcinosis 
that developed in transplanted kidneys found that cina-
calcet did not significantly decrease glomerular filtration 
rate or increase urinary calcium excretion [16–18]. To 
date, no strong evidence has been presented that sug-
gests that cinacalcet worsens kidney graft function or 
that it is associated with other severe adverse effects after 
transplantation. Urgent parathyroidectomy was recom-
mended by a previous case report to improve graft func-
tion in a poorly-controlled hyperparathyroidism patient 
who experienced graft dysfunction due to acute tubular 
necrosis associated with intratubular calcification [12]. 
The use of calcimimetic agent in this condition has not 
been previously reported. We demonstrated the efficacy 
of cinacalcet in decreasing serum intact PTH level and 
calcium level and improving graft function in a patient 
with poorly-controlled severe hyperparathyroidism 
who developed early graft dysfunction from intratubu-
lar calcium deposition immediately after transplanta-
tion. Immediate graft function in a setting of high urine 
pH and hyperparathyroidism-associated hypercalciuria 
and hyperphosphaturia may have caused calcium phos-
phate crystallization in this patient. During acute kidney 
injury, urine Ca/Cr ratio was found to be associated with 
furosemide and cinacalcet therapy. Whether the increase 
in the urine Ca/Cr ratio was due to high urine calcium 
or low urine creatinine has yet to be established. In any 
case, our patient’s kidney function was improved within 
one week after starting cinacalcet treatment, with accom-
panying decreases in serum calcium and iPTH. At time 
of discharge, our patient had good kidney function (SCr 
67.2  mg/dL), but still had a slightly elevated iPTH that 
ranged from 15.9 to 21.2 ng/L.
Conclusion
Severe hyperparathyroidism can cause early allograft 
dysfunction from intratubular calcium crystal obstruc-
tion after kidney transplantation. Perioperative treatment 
with cinacalcet was safe and effective in reversing the 
effects of nephrocalcinosis and improving kidney func-
tion in this patient.
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